Latest BRAF Stories
SAN DIEGO, May 14, 2014 /PRNewswire/ -- Trovagene, Inc.
BOULDER, Colo., May 14, 2014 /PRNewswire/ -- Array BioPharma Inc.
Polaris Group Scientific Colleagues from Several University Cancer Centers Present Data at 2014 AACR Meeting in San Diego, CA SAN DIEGO, April 29, 2014 /PRNewswire/ -- Polaris Group
Three Phase 3 Trials Advancing in Patients with BRAF Melanoma, NRAS Melanoma and Low-Grade Serous Ovarian Cancer BOULDER, Colo., April 23, 2014 /PRNewswire/ -- Following the recent
QUÉBEC CITY, April 9, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
Study results show correlation between mutational status and treatment response, as well as concordance between BRAF V600E mutation assay and tissue biopsy at baseline SAN DIEGO,
SAN DIEGO, April 1, 2014 /PRNewswire/ -- Trovagene, Inc.
The Highest Percentage of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next One to Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass.,
The Jeffrey Epstein VI Foundation backs the FDA's landmark decision to approve inhibitor cocktails for melanoma. NEW YORK, Feb.
Introducing CE-IVD marked kits with expanded mutation coverage in colorectal cancer for Kras, Nras, and Braf genes. Tarzana, Calif (PRWEB) January 29, 2014
- A volcanic mudflow.